Amantadine for fatigue in multiple sclerosis

Pucci, Eugenio; Tato, Pedro Brañas; D'Amico, Roberto; Giuliani, G.; Solari, Alessandra; Taus, Cristiana

doi:10.1002/14651858.cd002818.pub2

Cited by 117 publications

(70 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…116 In a more recent study, amantadine was compared to modafinil and acetyl-L-carnitine, as well as placebo. 117 The study demonstrated some benefit of amantadine over the other treatment arms at the one month assessment of MFIS score.…”

Section: Treatment Of Fatiguementioning

confidence: 99%

Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions

Brenner

Piehl

2016

Acta Neurol Scand

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neuroinflammatory condition with a prominent progressive neurodegenerative facet that typically affects young-or middle-aged adults. Although physical disabilities have been in the foreground by being easier to assess, there is an increasing interest in mental disabilities and psychiatric co-morbidities, which have a disproportionally high impact on important outcome measures such as quality of life and occupational disability. In particular, cognitive impairment, depression and mental fatigue, which mutually interact with each other, seem to be of importance in this context. In recent decades, major efforts have been invested in developing more effective disease modulatory treatments. This has resulted in novel therapeutic options and awareness of the importance of early intervention. In comparison, good quality and adequately powered studies on symptomatic treatments of fatigue and psychiatric co-morbidities in MS are rare, and awareness of treatment options is much lower. We here review the existing evidence base for symptomatic treatment of fatigue and depression in MS patients. With regard to fatigue, off-label prescription of alertness improving drugs is common, in spite of all but absent evidence of efficacy. In contrast, a number of smaller studies suggest that physical exercise and fatigue management courses may have some clinical benefit. Very few studies have addressed the efficacy of antidepressants and non-pharmaceutical interventions specifically in MS patients. Therefore, treatment guidelines largely rely on data from non-MS populations. In the future, there is a strong motive to direct additional resources to the study of these important aspects of MS. K E Y W O R D Scognitive symptoms, depression, fatigue, multiple sclerosis, treatment

show abstract

Section: Treatment Of Fatiguementioning

confidence: 99%

Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions

Brenner

Piehl

2016

Acta Neurol Scand

View full text Add to dashboard Cite

show abstract

“…In addition, evidence of the efficacy of antifatigue medications in patients with MS is mixed, suggesting that exclusion of subjects on antifatigue medication may not have biased the sample much. 39,40 The subjects in this study all noted fatigue as a significant symptom despite a wide range of disability, yet it is not known whether subjects on antifatigue medication would have reacted in a similar manner. Future studies could examine the effect of intermittent exercise on individuals with MS who are taking antifatigue medication.…”

Section: Discussionmentioning

confidence: 87%

Effect of a Single Bout of Intermittent versus Continuous Walking on Perceptions of Fatigue in People with Multiple Sclerosis

Karpatkin¹,

Rzetelny²

2012

International Journal of MS Care

View full text Add to dashboard Cite

Fatigue may limit the ability of people with multiple sclerosis (MS) to participate in walking exercises, which could ultimately reduce their benefit from physical therapy. An exercise program that minimizes the fatigue experienced by people with MS during exercise may lead to an increase in the amount of exercise being performed. The purpose of this study was to determine whether subjective feelings of fatigue differ in people with MS depending on whether they exercised intermittently or continuously. Using a within-subjects, counterbalanced crossover design, a sample of 30 individuals with MS performed 6 minutes of continuous and 6 minutes of intermittent walking 1 week apart. Fatigue was measured on the Visual Analogue Scale of Fatigue (VASF) and recorded before and after the walking conditions. A 2 × 2 repeated-measures analysis of variance was used to assess the potential effects of intermittent versus continuous walking on self-reported fatigue. A significant interaction revealed that pre-post mean self-ratings of fatigue on the VASF increased less in the intermittent condition (from 37.93 mm to 44.83 mm; difference = 6.90 mm) compared with the continuous condition (from 34.33 mm to 54.43 mm: difference = 20.10 mm) (P < .001), suggesting that patients experienced less fatigue in the intermittent condition despite walking an equivalent total duration. The interaction effect was not influenced by age, gender, disease severity or duration, use of antispasticity medication, use of assistive devices, or mood. The results suggest that people with MS may be more tolerant of, and able to perform, greater amounts of exercise if they exercise intermittently. Int J MS Care. 2012;14:124-131.

show abstract

“…Changes to circadian rhythms through lack of routine and disrupted sleep-wake patterns also perpetuate fatigue. 14 Currently, no approved medical treatment is available for MS-related fatigue in Germany, 15 and drug trials to date suggest poor efficacy. 16 However, behavioral treatment approaches have shown encouraging effects.…”

Section: Patient Interviews/focus Groupmentioning

confidence: 99%

Development and Feasibility of an Evidence-Based Patient Education Program for Managing Fatigue in Multiple Sclerosis

Wendebourg¹,

Feddersen²,

Lau³

et al. 2016

International Journal of MS Care

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system. Fatigue is a common and disabling symptom, often causing decreased quality of life, social withdrawal, and unemployment. We developed and studied the feasibility of a cognitive-behavioral group intervention to manage fatigue in MS. We aimed to integrate the concepts of cognitive-behavioral therapy and evidence-based patient information.

show abstract

Amantadine for fatigue in multiple sclerosis

Abstract: Cochrane Database of Systematic Reviews REFERENCES References to studies included in this review CMSRG 1987 {published data only} * The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis.

Cited by 117 publications

References 44 publications

Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions

Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions

Effect of a Single Bout of Intermittent versus Continuous Walking on Perceptions of Fatigue in People with Multiple Sclerosis

Development and Feasibility of an Evidence-Based Patient Education Program for Managing Fatigue in Multiple Sclerosis

Contact Info

Product

Resources

About